

## Dermatomyositis assessment of rash via telemedicine: a preliminary study

Sirs,

Dermatomyositis (DM) is a rare systemic autoimmune disease with prominent skin manifestations that significantly impact quality of life (1, 2). The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) is a validated clinician-scored instrument that measures skin disease activity (erythema, scale, ulceration) and damage (poikiloderma, calcinosis) (3). CDASI activity score (CDASI-a) >14 characterised moderate to severe disease, and a 4–5-point change reflected a minimal clinically significant change (4). However, CDASI requires clinical expertise and specialised training, especially for non-dermatologists or non-rheumatologists (5). We conducted a prospective proof-of-concept study to evaluate the feasibility of telemedicine-based CDASI-a compared with in-clinic evaluations. DM patients fulfilling the 2017 EULAR/ACR criteria were enrolled. Each patient underwent 2 clinic visits ≥2 months apart, each followed by telemedicine visit within 1 month (Supplementary Fig. S1). At each encounter, two independent rheumatologists (MD1 and MD2) scored the CDASI-a. During telemedicine visits, physicians used secure real-time video calls combined with standardised smartphone images submitted by patients via a specialised mobile application. The mobile application guided patients to obtain standardised images of the face, upper chest, upper back, and dorsal hands regardless of the presence of rash. Images were securely uploaded to a HIPAA-compliant server. Patient-reported outcome measures (PROMs), including Skindex-16 (6), itch scale (7), and patient global activity (PtGA), were collected during clinic visits. Spearman's correlation coefficient ( $r_{sp}$ ) evaluated correlations between modalities. Intraclass correlation coefficient (ICC) and Bland-Altman plot assessed inter-rater reliability.

Twenty-seven DM patients (median age 50, 81.5% female, 96.3% White, 48% anti-TIF1- $\gamma$  positivity) participated. The median time between the clinic visits and corresponding telemedicine visits was 14.0 days (IQR 13.0–19.0). Median clinic CDASI-a for all visits was 4.5 (IQR 1.0–12.0), and the corresponding telemedicine CDASI-a was 5.0 (IQR 1.0–11.0), with no significant difference ( $p=0.78$ ). Telemedicine CDASI-a was strongly correlated with clinic CDASI-a ( $r_{sp}=0.93$ ,  $p<0.001$ ) and all PROMs, indicating good convergent validity and comparable to those between clinic CDASI-a and PROMs (Table I).

Inter-rater reliability for telemedicine CDASI-a between MD1 and MD2 was excellent (ICC=0.85, 95%CI 0.73–0.92,  $p<0.001$ ). A Bland-Altman plot between MD1 and

**Table I.** Validity of telemedicine CDASI-a<sup>a</sup>.

Spearman rank correlation coefficients	Clinic CDASI activity (MD1)	Clinic CDASI Activity (MD2)	Skindex	Itch Scale	Patient global activity
Telemedicine CDASI-a (MD1)	<b>0.929</b> $p<0.001$ n=40	<b>0.866</b> $p<0.001$ n=40	<b>0.804</b> $p<0.001$ n=40	<b>0.563</b> $p<0.001$ n=40	<b>0.725</b> $p<0.001$ n=38
Clinic CDASI-a (MD1)	N/A	<b>0.923</b> $p<0.001$ n=40	<b>0.828</b> $p<0.001$ n=48	<b>0.480</b> $p=0.001$ n=48	<b>0.706</b> $p<0.001$ n=46
Telemedicine CDASI-a (MD2)	<b>0.875</b> $p<0.001$ n=42	<b>0.831</b> $p<0.001$ n=44	<b>0.717</b> $p<0.001$ n=44	<b>0.553</b> $p<0.001$ n=44	<b>0.691</b> $p<0.001$ n=42
Clinic CDASI-a (MD2)	<b>0.923</b> $p<0.001$ n=40	N/A	<b>0.809</b> $p<0.001$ n=50	<b>0.533</b> $p<0.001$ n=50	<b>0.753</b> $p<0.001$ n=48

CDASI-a: Cutaneous Dermatomyositis Disease Area and Severity Index activity score; MD1: first rheumatologist (primary treating rheumatologist).

<sup>a</sup>Higher CDASI-a, Skindex, Itch Scale, indicate higher disease severity.

MD2's log10 transformation of telemedicine CDASI showed good agreement (Supplementary Fig. S2). CDASI-a changes over time, measured via telemedicine, are moderately correlated with clinic-based changes ( $r_{sp}=0.45$ ,  $p=0.09$ ). The percentage agreement between the Clinic CDASI-a and telemedicine CDASI-a was 90.3% using the 5-point improvement threshold.

All the participants successfully used the video platform and submitted standardised self-photographs, with caregiver assistance as needed.

Our findings support the feasibility of telemedicine for cutaneous DM assessment. The telemedicine CDASI-a showed good validity, reliability, and responsiveness to change when compared to traditional clinic CDASI-a. These results are consistent with prior studies of remote evaluation of Psoriasis Area and Severity Index (PASI) and Hand eczema severity index (HECSI) using digital images and teledermatology (8–10). Limitations include small sample size, racial homogeneity (predominantly White), and overall mild disease activity. Recall bias is possible, since the same rheumatologists conducted both clinic and telemedicine assessments, although a 14-day separation reduces this concern. The rashes could have changed during that period and might also influence the results. While dermatologists did not participate in evaluations, prior work has demonstrated strong reliability between dermatologists and rheumatologists while performing CDASI (5).

In conclusion, this preliminary study demonstrates that remote skin disease activity assessment in DM using telemedicine and patient self-images is feasible. Larger studies including more diverse populations and broader disease activity are needed to validate these findings and further explore the utility of teledermatology in clinical trials and routine care.

N. PONGTAKULPANIT<sup>1,2</sup>, MD

A. BISHNOI<sup>3</sup>, MD

D.P. ASCHERMAN<sup>1</sup>, MD

S. MOGHADAM-KIA<sup>1</sup>, MD, MPH

C.V. ODDIS<sup>1</sup>, MD

R. AGGARWAL<sup>1</sup>, MD, MS

<sup>1</sup>Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, PA, USA; <sup>2</sup>Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand;

<sup>3</sup>Department of Dermatology, UPMC, Pittsburgh, PA, USA.

Please address correspondence to:

Rohit Aggarwal

Division of Rheumatology and Clinical Immunology,

University of Pittsburgh School of Medicine, 3601 Fifth Ave., Suite 2B, Pittsburgh, PA 15213, USA.

E-mail: aggarwalr@upmc.edu

Competing interest: R. Aggarwal has received research grants from Boehringer Ingelheim (BI), EMD Serono, Janssen, PRoivant, and Pfizer. He has received consulting fees from Abcuro, Alexion, ANI Pharmaceutical, Argenx, Astra-Zeneca, Boehringer Ingelheim, Bristol Myers-Squibb, CabaiettaBio, Capstanx, CSL Behring, Dren Bio, EMD Serono, Fate Therapeutics Inc, Galapagos, GlaxoSmithKline LLC (GSK), Horizontal Therapeutics, I-Cell, Immunovant, Janssen, Janux Therapeutics, Kinksa Pharmaceuticals, Lilly, Meiji Pharma, Novartis, Nakarta, Octapharma, Orna Therapeutics Inc, Ouro Medicines, Pfizer, PRoivant, Sun Pharmaceutical Industries, Tourmaline Bio, UCB and Verismo Therapeutics. All other authors declare no competing interests.

## References

- DEWANE ME, WALDMAN R, LU J: Dermatomyositis: Clinical features and pathogenesis. *J Am Acad Dermatol* 2020; 82(2): 267–81. <https://doi.org/10.1016/j.jaad.2019.06.1309>
- HUNDLEY JL, CARROLL CL, LANG W et al.: Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. *J Am Acad Dermatol* 2006; 54(2): 217–20. <https://doi.org/10.1016/j.jaad.2004.12.015>

## Letters to the Editors

3. YASSAEE M, FIORENTINO D, OKAWA J *et al.*: Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. *Br J Dermatol* 2010; 162(3): 669-73. <https://doi.org/10.1111/j.1365-2133.2009.09521.x>
4. ANYANWU CO, FIORENTINO DF, CHUNG L *et al.*: Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. *Br J Dermatol* 2015; 173(4): 969-74. <https://doi.org/10.1111/bjd.13915>
5. TIAO J, FENG R, BIRD S *et al.*: The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists. *Br J Dermatol* 2017; 176(2): 423-30. <https://doi.org/10.1111/bjd.15140>
6. CHREN MM, LASEK RJ, SAHAY AP, SANDS LP: Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. *J Cutan Med Surg* 2001; 5(2): 105-10. <https://doi.org/10.1007/BF02737863>
7. YOSIPOVITCH G, REANEY M, MASTEY V *et al.*: Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. *Br J Dermatol* 2019; 181(4): 761-9. <https://doi.org/10.1111/bjd.17744>
8. SINGH P, SOYER HP, WU J, SALMHOFER W, GILMORE S: Tele-assessment of Psoriasis Area and Severity Index: a study of the accuracy of digital image capture. *Australas J Dermatol* 2011; 52(4): 259-63. <https://doi.org/10.1111/j.1440-0960.2011.00800.x>
9. KOLLER S, HOFMANN-WELLENHOF R, HAYN D *et al.*: Teledermatological monitoring of psoriasis patients on biologic therapy. *Acta Derm Venereol* 2011; 91(6): 680-5. <https://doi.org/10.2340/00015555-1148>
10. BRUCH A, WEIGANDT W, SCHARDT Y, HERR R, BENECKE J, SCHMIEDER A: Improving Outcomes and Quality of Life for Patients with Hand and Foot Eczema: Randomized Study of a Patient-Centered Monitoring App. *J Med Internet Res* 2025; 27: e52159. <https://doi.org/10.2196/52159>